Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04UFM
|
||||
| Former ID |
DNC013279
|
||||
| Drug Name |
Dmt-Pro-Dmt-Phe-NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C35H43N5O6
|
||||
| Canonical SMILES |
CC1=CC(=CC(=C1CC(C(=O)N2CCCC2C(=O)NC(CC3=C(C=C(C=C3)O)C<br />)C(=O)NC(CC4=CC=CC=C4)C(=O)N)N)C)O
|
||||
| InChI |
1S/C35H43N5O6/c1-20-14-25(41)12-11-24(20)18-30(33(44)38-29(32(37)43)17-23-8-5-4-6-9-23)39-34(45)31-10-7-13-40(31)35(46)28(36)19-27-21(2)15-26(42)16-22(27)3/h4-6,8-9,11-12,14-16,28-31,41-42H,7,10,13,17-19,36H2,1-3H3,(H2,37,43)(H,38,44)(H,39,45)/t28-,29-,30-,31-/m0/s1
|
||||
| InChIKey |
VSPCTLNQMKBUFW-ORYMTKCHSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Delta-type opioid receptor | Target Info | Inhibitor | [1] | |
| Kappa-type opioid receptor | Target Info | Inhibitor | [1] | ||
| Mu-type opioid receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Opioid proenkephalin pathway | |||||
| Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signalingWP69:TCR Signaling Pathway | |||||
| Opioid Signalling | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.